Evolva reaches first milestone in IFF collaboration
Evolva Holding SA announced that International flavors & Fragrances Inc. (IFF) has confirmed that Evolva has achieved the first milestone in their collaboration that was announced in January 2011.
The ultimate objective of the collaboration is to implement a commercially viable biosynthetic route for the sustainable production of a key flavouring ingredient. Several targets have been defined to measure the progress of the project, including yield and manufacturing cost.
As the first major target in this project has been achieved, IFF will make a milestone payment to Evolva. The milestone payment does not change Evolva’s cash flow guidance for 2012.
Neil Goldsmith, CEO of Evolva, said, “Hitting a major project target ahead of schedule, is of course great news. The fact that we have just recently agreed on a second project with IFF, confirms our ability to deliver for demanding partners.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Swissmedic accepts Santhera's filing of SNT-MC17 in Friedreich's Ataxia
US Patent for Rapid Test Method and Technology Platform Awarded to MedMira
Vaccination as simple as putting on lotion - Nanotechnology lets vaccines get into the body without a pinprick
Merck Serono to Expand Research and Development Presence in China - China's Research and Development Organization Will Become the Fourth Key R&D Hub for Merck Serono Worldwide
Waters to Acquire Andrew Alliance
Immune system cells key to maintaining blood-brain barrier
Cytogen to Raise $20 Million Through Private Placement of Common Stock and Warrants

Neutralizing the SARS-CoV-2 sugar coat - Researchers may have found the “Achilles’ heel” of the virus
